Filtered By:
Specialty: Infectious Diseases
This page shows you your search results in order of relevance. This is page number 13.
Order by Relevance | Date
Total 742 results found since Jan 2013.
NIAID funds new influenza research network
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases has established a network of research sites to study the natural history, transmission and pathogenesis of influenza and provide an international research infrastructure to address influenza outbreaks. The program, called the Centers of Excellence for Influenza Research and Response (CEIRR), is expected to be supported for seven years by NIAID contracts to five institutions. Funding for the first year of the contracts will total approximately $24 million.
Source: EurekAlert! - Infectious and Emerging Diseases - April 14, 2021 Category: Infectious Diseases Source Type: news
Large NIH clinical trial will test polyclonal antibody therapeutic for COVID-19
(NIH/National Institute of Allergy and Infectious Diseases) A Phase 2/3 trial to evaluate a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2, called SAB-185, has begun enrolling non-hospitalized people with mild or moderate cases of COVID-19. The trial, ACTIV-2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The therapeutic was developed by SAB Biotherapeutics, Inc. (Sioux Falls, South Dakota).
Source: EurekAlert! - Infectious and Emerging Diseases - April 21, 2021 Category: Infectious Diseases Source Type: news
Clinical trial of therapeutics for severely ill hospitalized COVID-19 patients begins
(NIH/National Institute of Allergy and Infectious Diseases) A new Phase 3 trial to test the safety and efficacy of therapeutics for COVID-19 has begun enrolling patients hospitalized with life-threatening cases of COVID-19, including those with acute respiratory failure. The trial is supported by two components of the NIH, the National Institute of Allergy and Infectious Diseases (NIAID) and the National Heart, Lung and Blood Institute (NHLBI), and is part of the NIH Accelerating COVID-19 Treatment Interventions and Vaccines (ACTIV) public-private partnership.
Source: EurekAlert! - Infectious and Emerging Diseases - April 22, 2021 Category: Infectious Diseases Source Type: news
COVID-19 vaccine responses to be studied in people with immune deficits
(NIH/National Institute of Allergy and Infectious Diseases) A study assessing how people with immune system deficiencies or dysregulations respond to COVID-19 vaccination has begun enrolling participants at the National Institutes of Health Clinical Center in Bethesda, Maryland. The single-site study is led by researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and aims to enroll 500 people, 400 with primary or secondary immune system disorders and 100 without such conditions.
Source: EurekAlert! - Infectious and Emerging Diseases - April 23, 2021 Category: Infectious Diseases Source Type: news
Trial of existing antibiotic for treating Staphylococcus aureus Bacteremia begins
(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial to test the antibiotic dalbavancin for safety and efficacy in treating complicated Staphylococcus aureus (S. aureus) bacteremia has begun. The trial will enroll 200 adults hospitalized with complicated S. aureus infection at approximately 20 trial sites around the United States. The trial is being sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Source: EurekAlert! - Infectious and Emerging Diseases - April 27, 2021 Category: Infectious Diseases Source Type: news
Clinical Trial Evaluating Mixed COVID-19 Vaccine Schedules Begins
(NIH/National Institute of Allergy and Infectious Diseases) The National Institutes of Health has started a Phase 1/2 clinical trial in which adult volunteers who have been fully vaccinated against COVID-19 will receive booster doses of different COVID-19 vaccines to determine the safety and immunogenicity of mixed boosted regimens. The National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, is leading and funding the study through the Infectious Diseases Clinical Research Consortium, a clinical trials network.
Source: EurekAlert! - Infectious and Emerging Diseases - June 1, 2021 Category: Infectious Diseases Source Type: news
Prevalence and factors associated with adverse drug events among patients on dolutegravir-based regimen at the Immune Suppression Syndrome Clinic of Mbarara Regional Referral Hospital, Uganda: a mixed design study
CONCLUSION: This study reports a prevalence of 33.1% of ADEs among patients on DTG-based regimen. The most commonly experienced ADE was allergy. Male sex, early HIV disease stage at entry into care and detectable viral load at initiation of DTG-based regimen were significantly associated with ADEs. It is crucial to actively monitor patients with these characteristics for ADEs.PMID:35366917 | DOI:10.1186/s12981-022-00442-7
Source: AIDS Research and Therapy - April 3, 2022 Category: Infectious Diseases Authors: Angella Namulindwa John Hans Wasswa Winnie Muyindike Robert Tamukong Joseph Oloro Source Type: research
